1147 GMT - Novartis's 2025 guidance lift for both sales and profits should be well-received among investors, Jefferies analysts say in a note. The Swiss drugmaker's higher revenue, a better gross margin and lower R&D spend drove its core operating income above consensus, the analysts say. "We believe we could see a continuing beat-and-raise story this year," they say. Shares rise 0.7% to 94.04 euros.(helena.smolak@wsj.com)
(END) Dow Jones Newswires
Novartis shares rise 0.7% to 94.04 Swiss francs. "Novartis Guidance Lift Seems Positive Signal for Investors -- Market Talk," at 1147 GMT, misstated the currency.
(END) Dow Jones Newswires
April 29, 2025 07:54 ET (11:54 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。